Up to 80% of all NAFLD patients have normal range ALT levels and it also decreases as liver fibrosis progresses to liver cirrhosis37, so the results of our study may actually be on par with the progression of NAFLD. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.